Publication Name	World Journal of Critical Care Medicine
Manuscript ID	14536
Country	United States

Received	2014-10-10 12:17
Peer-Review Started	2014-10-10 19:17
To Make the First Decision	2014-11-27 12:22
Return for Revision	2014-12-03 19:48
Revised	2014-12-20 13:32
Second Decision	2015-02-10 16:16
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2015-02-12 14:21
Articles in Press	2015-02-12 14:21
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-04-07 12:06
Publish the Manuscript Online	2015-04-23 11:46

ISSN	2220-3141(online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Critical Care Medicine
Manuscript Type	Minireviews
Article Title	Tumor lysis syndrome: A clinical review
Manuscript Source	Unsolicited Manuscript
All Author List	Aibek E Mirrakhimov, Prakruthi Voore, Maliha Khan and Alaa M Ali
Funding Agency and Grant Number
Corresponding Author	Aibek E Mirrakhimov, MD, Department of Internal Medicine, Saint Joseph Hospital, 2900 N. Lake Shore, Chicago, IL 60657, United States. amirrakhimov1@gmail.com
Key Words	Cancer; Arrhythmia; Seizure disorder; Tumor lysis syndrome; Acute kidney injury
Core Tip	Tumor lysis syndrome (TLS) is characterized by a massive tumor cell death leading to the development of metabolic derangements and target organ dysfunction. TLS can occur as a result of cancer treatment or spon?taneously. Blood cancers constitute the vast majority of TLS cases because of the sensitivity to therapy and rapid division rates. Solid cancers comprise the minority of cases and are usually advanced if complicated by TLS. Prophylaxis is the mainstay of management and should be routinely implemented in high and intermediate risk patients. Management of established TLS includes intravenous hydration, urate lowering therapies, management of hyperkalemia and hemodialysis in refractory cases.
Publish Date	2015-04-23 11:46
Citation	Mirrakhimov AE, Voore P, Khan M, Ali AM. Tumor lysis syndrome: A clinical review. World J Crit Care Med 2015; 4(2): 130-138
URL	http://www.wjgnet.com/2220-3141/full/v4/i2/130.htm
DOI	http://dx.doi.org/10.5492/wjccm.v4.i2.130

Full Article (PDF)	WJCCM-4-130.pdf
Full Article (Word)	WJCCM-4-130.doc
Manuscript File	14536-Review.doc
Answering Reviewers	14536-Answering reviewers.pdf
Conflict-of-Interest Disclosure Form	14536-Conflict-of-interest statement.PDF
Copyright License Agreement	14536-Copyright assignment.pdf
Peer-review Report	14536-Peer-review(s).pdf
Scientific Misconduct Check	14536-Scientific misconduct check.pdf
Scientific Editor Work List	14536-Scientific editor work list.pdf